Publications
Representative Peer-reviewed Publications
Prediction of cytogenetic abnormalities with gene expression profiles. Blood. 2012.
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Sawyer, JR. Cancer Genet. 2011;204:3-12.
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Munshi NC, Anderson KC, Bergsagel PL, et al. Blood. 2011;117(18):4696-4700.
Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. Avet-Loiseau H, Magrangeas F, Moreau P, et al. J Clin Oncol. 2011;29(14):1893-1897.
The Use of Genetics Markers and Signatures in Multiple Myeloma Risk Stratification. American Society of Clinical Oncology. 2011.
Gene expression profiling advances in multiple myeloma. HemOnc Today. 2010.
A high-risk signature for patients with multiple myeloma established from human myeloma cell lines molecular classification. Haematologica. 2010.
The following article provides further validation of the work originally performed and published by John Shaughnessy, Ph.D., and Dr. Bart Barlogie, UAMS:
Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica. 2010.
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010.
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome. Journal of Clinical Onocology. 2008.
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009.
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2009.
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia. 2007.
The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009.
Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J and Barlogie B. High Incidence of Chromosome 13 Deletion In Multiple Myeloma Detected by Multi-Probe Interphase FISH. Blood. 2000; 96:1505-1511. PMID:10942398
Shaughnessy J, Gabrea A, Ying Q, Brents, L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, and Kuehl M. Cyclin D3 at 6p21 is dysregulated by recurrent Ig translocations in multiple myeloma. Blood. 2001; 98:217-223. PMID:11418483
Zhan, F, Hardin, J, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, Van Rhee F, Fassas A, Tricot G, Crowley J, Barlogie B, and Shaughnessy J. Global Gene Expression Profiling Of Multiple Myeloma, Monoclonal Gammopathy Of Undetermined Significance And Normal Bone Marrow Plasma Cells. Blood. 2002; 99:1745-1757. PMID:1181292
Zhan F, Tian E, Bumm K, Smith R, Barlogie B, and Shaughnessy J. Gene Expression Profiling of Normal Human Plasma Cell Differentiation and the Classification Of Multiple Myeloma Based on Similarities to Distinct Stages of Late Stage B-Cell Development. Blood. 2003; 101:1128-1140. PMID:12393520
Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004; Oct;17(10):1217-1222. PMID: 15195108
Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant. 2005;35(3):215-224. PMID: 15543196
Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer J, Holmig K, Zangarri M, Pineda-Roman M, Van Rhee F, Cavallo F, Burington B, John Crowley J, Tricot G, Barlogie B, and Shaughnessy Jr. J. Frequent Gain of Chromosome Band 1q21 in Plasma Cell Dyscrasias Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and is Related to Prognosis and Disease Progression Following Tandem Stem Cell Transplantation. Blood. 2006; 108:1724-1732. PMID:16705089
Shaughnessy JD Jr, Barlogie B. Using genomics to identify high-risk Myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12 (1 Suppl 1):77-80. PMID:16399589
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-2028. PMID:16728703
Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007; 13(23):7073-7079. PMID:18056185
Zhan F, Barlogie B, Arzoumanian V, Huang Y, Hollmig K, Zangarri M, Pineda-Roman M, Van Rhee F, Tricot G, Dhodapkar M, and Shaughnessy Jr. J. Gene Expression Signature Of Benign Monoclonal Gammopathy Evident In Multiple Myeloma Is Linked To Good Prognosis. Blood. 2007; 109:1692-1700. PMID:17023574
Shaughnessy Jr. J, Zhan F, Burington B, Huang Y, Hanamura I, Hollmig K, Zangarri M, Pineda-Roman M, Van Rhee F, Tricot G, Crowley J, and Barlogie B. A Validated Gene Expression Signature of High Risk Multiple Myeloma is Defined by Deregulated Expression of Genes Mapping to Chromosome 1. Blood. 2007; 109:2276-2284. PMID:17105813
Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M,Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple Myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007; 137:530-536. PMID:17489983
Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008; 111(2):968-969. PMID:18182586
Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr, Anaissie E, Crowley J, Barlogie B. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia. 2008; 22(4):850-855. PMID: 18200039
Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr., Tricot G, Zangari M, Zeldis J, Barer S, Crowley J. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115-3121. PMID: 18492953
Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Cytogenetic abnormalities in multiple myeloma: poor prognosis is linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol. 2009;145(5):637-641. PMID: 19344415
Nair, Shaughnessy JD Jr, Zhou Y, Cartron AM, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total therapy 2 predicts subsequent survival. Blood. 2009; 113(26):6572-6575. PMID:19389881
Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009; 23(11): 1941-1956. PMID: 19657360
Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood. 2010; 115(21): 4168-4173. PMID: 20124509
Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD Jr. High-risk myeloma is associated with global elevation of MiRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA. 2010; 107(17): 7904-7909. PMID: 20385818